chrisvoncsefalvay/vaers-outcomes huggingface dataset:
it felt like torture and she was in a fetal position to try to relieve the pain; clear drainage; congestion; slight cough; tiredness; Tested positive for Covid after both vaccines; Tested positive for Covid after both vaccines; lost her voice; lost her sense of smell and taste; lost her sense of smell and taste; paralyzing painful chills; This is a spontaneous report from a contactable consumer (patient). A 43-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection), via an unspecified route of administration, administered in Arm Right on an unknown date in Feb2021 (Lot number was not reported, age at vaccination: 42-year-old) as dose 2, single, and dose 1 via an unspecified route of administration, administered in Arm Right on an unknown date in Feb2021 (Lot number was not reported, age at vaccination: 42-year-old) as dose 1, single for Covid-19 immunisation. The facility where the vaccine was administered was vaccination site set up at a pharmacy staffed by hospital staff. Medical history included ongoing ITP Blood disorder (immune thrombocytopenic purpura) and believes she was diagnosed in 2004, she does not have a spleen from an unknown date and unknown if ongoing (she tends to get sicker and stay sicker longer than most people). The patient's concomitant medications were not reported. The patient reported that as she had an autoimmune disorder, she got the vaccine to protect herself and others. She believes the vaccine kept her out of the hospital. On 05Aug2021, the patient tested positive for covid after both vaccines and symptoms includes lost her voice, lost her sense of smell and taste, paralyzing painful chills, it felt like torture and she was in a fetal position to try to relieve the pain, clear drainage, congestion, slight cough, tiredness. The patient was quarantined until 14Aug2021. For the most part she was recovered but not one hundred percent. No additional Vaccines Administered on Same Date of the Pfizer Suspect. The patient did not visit any emergency room or physician office due to events. No prior Vaccinations (within 4 weeks) prior to the first administration date of the suspect vaccines. No predisposing factors, no Antipyretic Use (around the date(s) of Vaccination). She has been told different information as to when after having Covid, she can get a booster shot and also called the local Department of Health and they did not know, and told her to call Pfizer. She want to known when can she take the booster shot after having Covid. The patient was encouraged to speak to her healthcare provider regarding some of her concerns and agent provides a 6 digit Interaction number and hours of operation of Monday through Friday, from 8AM to 8PM EST. The patient underwent lab tests and procedures which included covid test: positive on 05Aug2021 (Caller states she got a nose swab only). The outcome of event it felt like torture and she was in a fetal position to try to relieve the pain was unknown and other events resolved on 14Aug2021.  The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.
Menstrual Period Irregularity, i.e., patient taking Yasmin drospirenone and ethinyl estradiol active hormonal pills began menses
I took Tylenol before I went to get the vaccine. My arm broke out in a rash, and it went on for two weeks. I have been putting a steroid cream on the rash and it helps. I had a headache and a fever. I tried to work a 10-hour shift and it I could not work all the shift I had to go home.
Tdap was administered IV instead of IM.  Ordered at the same time as morphine IV.  RN scanned both at bedside at same time but mixed up routes of administration when administering.  Both were in prefilled syringes, and she knew which to give which route of administration, but she mixed them up in her hands
This case was reported by a pharmacist via call center representative and described the occurrence of muscle pain in a 53-year-old female patient who received SHINGRIX (batch number T5242, expiry date March 2020). On 2nd April 2018 14:00, the patient received the 1st dose of SHINGRIX (subcutaneous). In April 2018, less than a week after receiving SHINGRIX, the patient experienced muscle pain and intramuscular formulation administered by other route. On an unknown date, the outcome of the muscle pain and intramuscular formulation administered by other route were unknown. It was unknown if the reporter considered the muscle pain to be related to SHINGRIX. Additional details were provided as follows: The health care professional reported that the patient inadvertently received a dose of SHINGRIX via subcutaneous route, which led to incorrect route of administration. The health care professional did not have any further details regarding the muscle pain. No further information was reported.
I think I just began to notice a very slight headache in the left temple area around the end of September 2022. It wasn't debilitating or keeping me from working, but it was constant. I had a physical with my doctor on 11/29/2022 where I mentioned the headaches to her. She listened to my neck and did some tests and sent me for a brain scan. Everything came back fine though. I still have the headache as well as some tingling in from the nose down on my face and on the back of my head. I did recently receive some ARESTIN gum injections though as well.
Right upper arm pain at a 9 on scale of 1 to 10 woke me up at 12:40 AM 2/18/2021. at 6:00 AM took 1,000 mg of Tylenol for pain brought it to a 3 if I didn't move arm. Continued at a level 7 on 2/19/2021 at 5:30 AM too 500 mg Tylenol and at 6:00 AM took another 500 mg.  Pain continues now at 7:17 am at a level 2. 2/18/2021 diarrhea began about 8:00 am and continued until about 11:00 am.  It wasn't severe but between the two side effects I could not go to work .
This spontaneous report as received from nurse refers to 2 patients of unknown age. No concomitants were reported. On 23-MAY-2014, the patients were vaccinated with VAQTA INJ, K000943, expiration date 26-SEP-2016 (dose, frequency, route of administration and indication were not provided) that was exposed to 8.8C for 10 days. No adverse effects reported. No product quality complaint (PQC) was involved. The outcome of events was unknown. On 02-JUN-2014 a phone call was placed to reporter. The receptionist stated they do not have any one by that name employed at this facility. No further information is available at this time. This report is linked to 1405USA013915 and 1405USA013916, 1406USA004906, 1406USA004908, 1406USA004908, 1406USA004909, 1406USA004913, 1406USA004914, 1406USA004915, 1406USA004863, 1406USA004874, 1406USA004881, 1406USA004891, 1406USA004896, 1406USA004897, 1406USA004900, 1406USA004901, 1406USA004814, 1406USA004830, 1406USA004831, 1406USA004832, 1406USA004833, 1406USA004835, 1406USA004837 by the same reporter link. Additional information is not expected.
Pt. states that after receiving the 1st dose of J&J 08/08/2021, started experiencing symptoms 08/09/2021 of nausea, hives through out the body (including face), fever, and fatigue. Urgent Care visit 08/09/2021 treated with Benadryl, Zortec, and Pepcid. Still continuing with minor hives remaining.
1st dose 2 years ago, 2nd not received; This non-serious case was reported by a other health professional via call center representative and described the occurrence of incomplete course of vaccination in a 79-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received 2 years ago from reporting).   On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced incomplete course of vaccination (Verbatim: 1st dose 2 years ago, 2nd not received). The outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK Receipt date: 13-MAR-2023 The reporter asked if she could administer the second dose or if the patient had to start over with the vaccination. Consent for follow up was not requested. Till the time of reporting, the patient did not receive the 2nd dose of Shingrix, which led to incomplete course of vaccination.
Vaccine is placed in refrigerator on 04Nov2021 and administered on 08Nov2021; doses were given after expiration date; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (doses were given after expiration date) and PRODUCT STORAGE ERROR (Vaccine is placed in refrigerator on 04Nov2021 and administered on 08Nov2021) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 008C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 08-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (doses were given after expiration date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine is placed in refrigerator on 04Nov2021 and administered on 08Nov2021). At the time of the report, EXPIRED PRODUCT ADMINISTERED (doses were given after expiration date) and PRODUCT STORAGE ERROR (Vaccine is placed in refrigerator on 04Nov2021 and administered on 08Nov2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No Concomitant information was reported. There was no temperature excursion. The reporter reported that that there was a confusion between the expiration date printed in the carton and the expiration date when the code was scanned and No adverse event was reported by patient.  No Treatment information was reported.
This spontaneous report was received from a registered nurse, referring to multiple unspecified patients of unknown age and gender. Information regarding the patients' medical history, concurrent conditions and concomitant medication were not reported. On unspecified dates, patients were administrated improperly stored doses of VAQTA (lot # and expiration date were not reported). It was reported that the vaccine was exposed for 270 hours at 9 C degrees. No adverse effects were reported. It was reported that all the vaccines were back in range. Digital data logger was reported as yes.  This is one of the several reports received from the same reporter. Additional information has been requested.
w/in 6hr of vax pt began to scream inconsolable & cont for hr;t104;taken to ER by amb-told was vax rxn given Ibuprofen & APAP;well by 24hr more than 3hr cont cry;had DT 11JUL96 w/no problems;
PATIENT RECEIVED BIVALENT VACCINE ON 12/2/22 AND AGAIN ON 12/22/22 IN ERROR.  WATCHING FOR ADVERSE EFFECTS BUT NONE NOTED TO DATE.
Information has been received from a physician concerning a pediatric patient who was vaccinated with a dose of Varivax. Subsequently the patient developed a mild case of chickenpox. No further information is available. Additional information has been requested.
Swollen and very painful lymph glands in left armpit/left side. Treated with ibuprofen 400 mg twice, five hours apart; pain has not changed yet however.
This spontaneous report as received from a licensed practical nurse refers to a 13 year old patient of unknown gender. The patient's medical history, concurrent conditions and concomitant medications were not reported. On 09-NOV-2015, the patient was vaccinated with the dose of GARDASIL (lot # L010596, expiration date unknown; dose and route were not reported) that had experienced an excursion. No adverse reaction was reported. This is one of several reports received from the same reporter. Additional information has been requested.
Narrative:  SORENESS CONTINUES BUT NO LONGER REQUIRING MEDICATION. CONTINUES WITH WARM COMPRESSES Symptoms:  & SORENESS AT INJECTION SITE Treatment:
Information has been received from a physician concerning a 14 year old female who on 11-SEP-1996 was vaccinated with the first dose of MMR II (route, site dose and lot number not reported).  On 21-JUN-1999, the patient was vaccinated with the second dose of MMR II (route, site dose and lot number not reported.  On 18-NOV-2009, the patient experienced mumps (thought the date diagnosed was reported as 11-NOV-2009).  The reporter felt that mumps was not related to therapy with MMR II.  The patient was afebrile and had not parotitis.  The outcome for mumps was not reported.  Follow up information has been received concerning the 14 year old female patient who on 11-SEP-1996 and on 21-JUN-1999 was vaccinated with the first and second doses of MMR II (route, and lot # unknown), respectively.  On 11-NOV-2009 (also reported as 18-NOV-2009) the patient experienced mumps (she was diagnosed on 13-NOV-2009 (also reported as 11-NOV-2009)).  The patient was afebrile and had R parotitis (also reported as not having parotitis).  On 13-NOV-2009, a serum IgM was negative, on an unspecified date an IgG and a serum amylase tests were performed and the results were 5.59 and 43, respectively.  At the time of the report the patient's outcome was unknown.  This is one of several reports from the same source.  No further information is available.
The events happened within two weeks of my receiving the fourth dose of the Pfizer COVID-19 vaccine. There was significant shoulder pain bilaterally, and it was more pronounced in the right shoulder than in the left. It radiated from the anterior of the shoulder into the clavicle at first. It also radiated from the shoulder to the elbow for about six months. The pain then became significantly worse, and it then radiated to the hand for the last two months. The aforementioned gradual radiation of the pain only affected the right arm. At that point, I went to my PCP, who referred to an orthopedist. My PCP prescribed Norco 5/325, which was not effective in treating the pain. I then saw the orthopedist, who ran X-rays of the right shoulder. The orthopedist diagnosed me with significant right rotator cuff calcification tendinopathy within the resorptive phase with associated severe subacromial subdeltoid calcific bursitis. There are no measurements indicated, but they are abnormally large. The orthopedist also prescribed me 50mg of tramadol, which I was to take every six to eight hours as needed. It reduced the pain significantly more than Norco did.  I have undergone barbotage to have the calcifications broken up, and only 70% could be broken up. The procedure had to be halted after 70% of the calcifications had been removed, because further barbotage would have damaged the tendon. I am currently undergoing physical therapy once a week. After having had the barbotage procedure completed and the physical therapy commenced one week thereafter, the range of motion is now normal. In certain positions in the right shoulder, the range of motion is normal, but with some other positions, there is weakness.
arm swelled; hot at injection site; This is a spontaneous report received from a contactable consumer reported that:  A 78-years-old female patient received bnt162b2 (BNT162B2; solution for injection), dose 2 via an unspecified route of administration, administered in Arm Left on 03Feb2021 17:30 (Batch/Lot Number: EL1283) as single dose and on 13Jan21 receveid BNT162b2 (Lot#EL0142)as single dose for covid-19 immunisation. The patient medical history was unknown. The patient's concomitant medications were unknown. On an unspecified date, the patient experienced arm swelled, hot at injection site. After 2nd day, occurred after 4th day. number of previous doses was 2nd shot. Outcome of the events were unknown.
Symptoms started around 10:40AM, 1 1/2 hours after administration.  Employee complained of being dizzy and tingly tongue, then developed hives, and shortness of breath.  Employee went to ED and received fluids.
VACCINE STORED AT IMPROPER TEMPERATURES. PT STATED A SOFTBALL SIZE LUMP APPEARED ON RD POST IMMUNIZATION. PT DENIES ITCHING OR REDNESS. PT STATED LUMP WAS HARD TO THE TOUCH. PT INFORMED THIS NURSE THAT SHE HAD A SIMILAR REACTION POST FIRST VACCINATION.
Breakthrough case admission after three vaccines Moderna 4/29/21 Lot# 23C31A;  Moderna 5/27/21 Lot# 33C21A;  Moderna 12/3/21 Lot# 078J21A
he was sick and could not get the second dose; missed his 2nd dose on March 6, 2021; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program. The reporter is the patient.  A male patient received bnt162b2 (BNT162B2), administration date 13Feb2021 (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: ILLNESS (non-serious), outcome "unknown", described as "he was sick and could not get the second dose"; PRODUCT DOSE OMISSION ISSUE (non-serious), outcome "unknown", described as "missed his 2nd dose on March 6, 2021". Additional information: Patient got the 1st dose of the vaccine on 13Feb2021 and missed his 2nd dose on 06Mar2021. Patient wanted to reschedule his 2nd dose, he was sick and could not get the second vax and now was asking to schedule again. He stated he had contacted the health department and was told to contact. The patient was only getting the run around and was fed up with this and hung up.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Shortness of breathe around 10Jan2021; This spontaneous case was reported by a consumer and describes the occurrence of DYSPNOEA (Shortness of breathe around 10Jan2021) in a 68-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039K20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event. Concomitant products included VALSARTAN (DIOVAN), HYDROXYCHLOROQUINE, MONTELUKAST and PRAVASTATIN for an unknown indication.   On 06-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced DYSPNOEA (Shortness of breathe around 10Jan2021). At the time of the report, DYSPNOEA (Shortness of breathe around 10Jan2021) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       This case was linked to MOD-2021-030436 (Patient Link).
Loose bowels, sometimes diarrhea.  Urgency to go during the day.  Not regular bowel activity.
Lips/tongue/throat swelling with pain of a deep bruise, skin burn like hot peppers. SOB eyes swollen shut. Went away after 5 hours.
Episode of atrial fibrillation, first event on 12/20/21. Onset after lunch while on vacation. Seen in ER. treated with diltiazem and metoprolol with return to sinus rhythm
Headache, joint pain, muscle pain, swollen injection site, rash at the injection site, fatigue. Feels like the flu
Patient fainted the following morning and was seen in the emergency room at hospital after hitting her head when fainting. Also had a slight fever post-vaccination.
This case was reported by a nurse and described the occurrence of vision disturbance in a 20 year old female patient who received hepatitis B vaccine recombinant. The patient's medical history was notable for visual disturbance and fatigue following administration of Vicoden, and myopia corrected with glasses. On 6/24/04, the patient received the first dose of Engerix-B (lot ENG5540A2). On the same day, the patient received a Tuberculin skin test. At an unspecified time following the administration of Engerix-B, on 6/24/04, the patient experienced reduced visual acuity, vision disturbances characterized as haziness and  feeling of pressure in both eyes, fatigue, headache, and dizziness. The patient sought medical attention, however, no lab tests or vision tests were performed. The events resolved on 6/25/04. Comment: Reduced visual acuity was assessed as medically serious (OMIC).
On the day after she received the flu shot, the patient reports that her left arm became red, warm, swollen and itchy around the site of the vaccination.  She also had a migraine and vomiting on that day.  She went to employee health and was told to report her symptoms to the flu hotline number.  On 9/21 when patient called the hotline, the red area was the size of her palm.  It was not yet resolving or worsening. She was going to make an appt with her doctor.  Phone message left to check on symptoms on 9/27.  Patient has not returned my phone call.
Joint soreness in my hips making standing, walking, and sitting very uncomfortable and painful. Skin highly sensitive and tender to the point where it was unpleasant to have my clothes brush it. Head congestion and fullness, terrible headache and pressure behind my eyes. Sore throat and dry mouth.
The day after receiving the 3rd Pfizer COVID-19 shot on 11/24/2021, patient experienced itching of her upper arms and shoulders. Almost a month later, the itching still has not resolved. Mild rash/bumps developed on the patient yesterday, December 21, 2021.
left arm soreness - pain radiating down arm to thumb & pain with movement (immediately after vaccination)  unable to lift arm above chest height (4 hours after vaccination)  mild burning sensation in upper left arm (4 hours after vaccination)
itches.; Large red circle,; hot to touch; hard and itches.; This is a spontaneous report from a contactable consumer (patient). A 69-year-old non pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number was not reported), via an unspecified route of administration, administered in Arm Left on 19Feb2021 13:15 at the age of 69-year-old as dose 1 single for covid-19 immunisation. Medical history included chronic obstructive pulmonary disease (COPD), hypertension and augment allergy. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient was not diagnosed with covid prior to vaccination and patient was not tested for COVID-19 post vaccination. Concomitant medications included fluticasone furoate, umeclidinium bromide, vilanterol trifenatate (TRELEGY ELLIPTA), salbutamol (ALBUTEROL HFA) and olmesartan all taken for an unspecified indication, start and stop date were not reported.  The patient experienced large red circle, hot to touch, hard and itches on 03Mar2021 17:30. The patient did not receive any treatment in response to the events. The outcome of the events was not recovered.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected
Patient was administered vaccine on 2/17/22 that had expired on 2/12/22.
ACUTE RESPIRATORY FAILURE 3/20/2023  --  RECURRENCE OF HOSPITALIZATION WITH SAME SYMPTOMS
patient stated she had adverse reaction to vaccine following day. stated she was doing garden work outside and became itchy and had rash afterwards. patient unaware if rash is contact dermatitis or hives. doctor not able to confirm hives. doctor also stated she should not have gotten both vaccines on the same day
had a mild cold last night but it is gone now; This is the spontaneous report received from a contactable consumer (the patient). A 23-year-old-female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number was unknown) via an unspecified route of administration on an unspecified date at single dose for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. The caller stated she was supposed to have the second dose of the vaccine "today" but had a mild cold last night (onset date not specified) but it was gone currently. The outcome of the event was recovered on an unspecified date.  Information about lot/batch number cannot be obtained. No further information expected.
red, itchy, 3 1/2 inch swelling. Painful to touch.
Vaccine administered on 12-4. Myalgia of all muscles on 12-5 - Weakness - Was able to work, but constant pain: treated with ADVIL. On Dec 9, sx started to subside.